Abstract
New inhibitors are urgently needed to overcome the burgeoning problem of drug resistance in the treatment of Plasmodium falciparum infection. Targeting the folate pathway has proved to be a powerful strategy for drug development against rapidly multiplying systems such as cancer cells and microorganisms. Antifolates have long been used for malaria treatment but, despite their success, much less is known about parasite folate metabolism than about that of the human host. In this article, we focus on folate enzymes used clinically as anticancer drug targets, in addition to those that have potential to be used as drug targets, for which there are inhibitors at various stages of development. We discuss how this information could lead to the identification of new targets in malaria parasites.
| Original language | English |
|---|---|
| Pages (from-to) | 292-298 |
| Number of pages | 7 |
| Journal | Trends in Parasitology |
| Volume | 21 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 2005 |
| Externally published | Yes |
Bibliographical note
Funding Information:This work was supported by the Wellcome Trust (grants 056769, 056845, 062372, 067201 and 073896), the Biotechnology and Biological Sciences Research Council (grant 36/JE616379) and the NIH (Fogarty International grant TW 01186). A.N. and K.M. thank the Wellcome Trust for personal support. S.A.W. thanks the Wellcome Trust for institutional support. We apologize to those authors whose work was not cited because of space limitations.
ASJC Scopus subject areas
- Parasitology
- Infectious Diseases